Management of Viral Hepatitis in Solid Organ Transplant Recipients

Elizabeth Buganza-Torio; Karen Elizabeth Doucette

doi:10.1016/j.idc.2018.04.010

Management of Viral Hepatitis in Solid Organ Transplant Recipients

Infect Dis Clin North Am. 2018 Sep;32(3):635-650. doi: 10.1016/j.idc.2018.04.010.

Authors

Elizabeth Buganza-Torio¹, Karen Elizabeth Doucette²

Affiliations

¹ Division of Gastroenterology, University of Alberta, 11350 83 Avenue, Edmonton, Alberta T6G2G3, Canada.
² Division of Infectious Diseases, University of Alberta, 11350 83 Avenue, Edmonton, Alberta T6G2G3, Canada. Electronic address: [email protected].

PMID: 30146027
DOI: 10.1016/j.idc.2018.04.010

Abstract

With potent nucleos(t)ide analogue (NA) therapy, hepatitis B virus (HBV) is now an uncommon indication for liver transplant (LT) in North America. NA therapy, with or without hepatitis B immunoglobulin, results in low recurrence rates and excellent outcomes after LT. Direct-acting antiviral therapy for hepatitis C virus (HCV), results in cure in most patients, either before or after transplant. There are now descriptions of good clinical outcomes of transplant from HBV and HCV infected donors, as treatments are so effective and well tolerated. Hepatitis E virus in transplantation requires a high suspicion to diagnose and optimal therapy remains incompletely defined.

Keywords: Hepatitis B virus; Hepatitis C virus; Hepatitis E virus; Kidney transplantation; Liver transplantation; Thoracic transplantation.

Publication types

Review

MeSH terms

Antiviral Agents / therapeutic use*
Hepatitis, Viral, Human / complications*
Hepatitis, Viral, Human / drug therapy*
Humans
Immunocompromised Host
Organ Transplantation*
Viral Load

Substances

Antiviral Agents